Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001359

Prednisolone for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1,4-pregnadiène-11β,17α,21-triol-3,20-dione, 11β,17α,21-trihydroxy-1,4-pregnadiène-3,20-dione

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H28O5
Numéro CAS:
50-24-8
Poids moléculaire :
360.44
Numéro Beilstein :
1354103
Numéro MDL:
MFCD00003649
Code UNSPSC :
41116107
ID de substance PubChem :
329831381
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

prednisolone

Fabricant/nom de marque

EDQM

Pf

240 °C (dec.) (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2([H])[C@@H](O)C[C@@]4(C)[C@@]3([H])CC[C@]4(O)C(CO)=O)=C1

InChI

1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

Clé InChI

OIGNJSKKLXVSLS-VWUMJDOOSA-N

Informations sur le gène

human ... NR3C1(2908)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Prednisolone for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1043

Prednisolone, Pharmaceutical Secondary Standard; Certified Reference Material

P2700000

Prednisolone, European Pharmacopoeia (EP) Reference Standard

P2800000

Prednisolone 21-acetate, European Pharmacopoeia (EP) Reference Standard

P2810000

Prednisolone sodium phosphate, European Pharmacopoeia (EP) Reference Standard

Y0001355

Prednisolone for system suitability, European Pharmacopoeia (EP) Reference Standard

P2805000

Prednisolone pivalate, European Pharmacopoeia (EP) Reference Standard

Y0000582

Prednisolone 21-acetate, European Pharmacopoeia (EP) Reference Standard

1557000

Prednisolone sodium phosphate, United States Pharmacopeia (USP) Reference Standard

1555005

Prednisolone, United States Pharmacopeia (USP) Reference Standard

1556008

Prednisolone 21-acetate, United States Pharmacopeia (USP) Reference Standard

1556507

Prednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard

1558003

Prednisolone tebutate, United States Pharmacopeia (USP) Reference Standard

BP464

Prednisolone, British Pharmacopoeia (BP) Assay Standard

BP292

Prednisolone sodium phosphate, British Pharmacopoeia (BP) Assay Standard

PHR1630

Prednisolone 21-acetate, Pharmaceutical Secondary Standard; Certified Reference Material

BP1140

Prednisolone 21-acetate, British Pharmacopoeia (BP) Reference Standard

PHR2556

Prednisolone Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material, certified reference material, pharmaceutical secondary standard

PHR2557

Prednisolone Impurity I, certified reference material, pharmaceutical secondary standard

PHR2328

Prednisolone Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2816

Prednisolone Sodium Phosphate, certified reference material, pharmaceutical secondary standard

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360FD

Classification des risques

Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 2

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Axel Heidenreich et al.
European journal of cancer (Oxford, England : 1990), 50(6), 1090-1099 (2014-02-04)
Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel. Subsequently, compassionate-use programmes (CUPs) and expanded-access programmes (EAPs) were established worldwide, allowing access to cabazitaxel before
J A P Spijkers-Hagelstein et al.
Leukemia, 28(4), 761-769 (2013-08-21)
Successful treatment results for MLL-rearranged Acute Lymphoblastic Leukemia (ALL) in infants remain difficult to achieve. Significantly contributing to therapy failure is poor response to glucocorticoids (GCs), like prednisone. Thus, overcoming resistance to these drugs may be a crucial step towards
Alexander W Hauswirth et al.
Leukemia research, 28(3), 249-257 (2003-12-23)
Aggressive systemic mastocytosis (ASM) is a hematopoietic neoplasm characterized by infiltration of visceral organs by neoplastic mast cells (MCs) with consecutive organopathy and respective clinical and laboratory findings (so called C-Findings). Whereas, it is generally appreciated that patients with ASM
Arzu Didem Yalcin et al.
Clinical laboratory, 59(5-6), 681-685 (2013-07-20)
Here, we report the first case of patient with intracranial tumors (ICT) who developed a cutaneous adverse drug reaction during lansoprazole and prophylactic anticonvulsant treatment. SCORTEN is a scoring system used to predict mortality in TEN patients. If SCORTEN index
Vappu Rantalaiho et al.
Annals of the rheumatic diseases, 73(11), 1954-1961 (2013-08-03)
To study whether adding initial infliximab to remission-targeted initial combination-DMARD treatment improves the long-term outcomes in patients with early rheumatoid arthritis (RA). Ninety-nine patients with early, DMARD-naïve RA were treated with a triple combination of DMARDs, starting with methotrexate (max
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique